Early identification of hERG liability in drug discovery programs by automated patch clamp

Frontiers in Pharmacology

Volumn 5 AUG, Issue , 2014, Pages

  Danker, Timm ^a   Möller, Clemens ^b  

^a NMI TT GmbH   (Germany)

^b ALBSTADT SIGMARINGEN UNIVERSITY   (Germany)

Author keywords

ADMET; Automated patch clamp; Cardiac arrhythmia; Electrophysiology; HERG; Ion channel; Safety pharmacology; Torsades de pointes

Indexed keywords

ION CHANNEL; POTASSIUM CHANNEL HERG; SODIUM CHLORIDE; TERFENADINE; CISAPRIDE;

ANALYTICAL EQUIPMENT; ANIMAL CELL; ARTICLE; ARTIFACT; AUTOMATED PATCH CLAMP; CHANNEL GATING; CHO CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RESEARCH; DRUG SCREENING; ELECTROPHYSIOLOGY; INFORMATION PROCESSING; INTERMETHOD COMPARISON; NONHUMAN; PATCH CLAMP TECHNIQUE; PLANAR PATCH CLAMP; QUALITY CONTROL; CULTURE MEDIUM; DOSE RESPONSE; DRUG INDUSTRY; HEART ARRHYTHMIA; HUMAN; MEDICINAL CHEMISTRY; MEMBRANE RESISTANCE; THAWING;

EID: 84906257709     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00203     Document Type: Article

References (38)

1. Anderson JT, Campbell M, Wang J, Brunden KR, Harrington JJ, and Stricker-Krongrad A et al. 2010. Investigation of 4-piperidinols as novel H3 antagonists. Bioorg. Med. Chem. Lett. 20: 6246-6249.
2. Bahl A, Barton P, Bowers K, Brough S, Evans R, and Luckhurst CA et al. 2012. The discovery of CCR3/H1 dual antagonists with reduced hERG risk. Bioorg. Med. Chem. Lett. 22: 6688-6693.
3. Becker N, Stoelzle S, Göpel S, Guinot D, Mumm P, and Haarmann C et al. 2013. Minimized cell usage for stem cell-derived and primary cells on an automated patch clamp system. J Pharmacol Toxicol Methods 68: 82-87.
4. Becknell NC, Dandu Rr, Lyons JA, Aimone LD, Raddatz R, and Hudkins RL. 2012. Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists. Bioorg. Med. Chem. Lett. 22: 186-189.
5. Bruin ML, Pettersson M, Meyboom R, Hoes AW, and Leufkens HG. 2005. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur. Heart J. 26: 590-597.
6. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, and Keating MT. 1995. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80: 795-803.
7. Davenport AJ, Möller C, Heifetz A, Mazanetz MP, Law RJ, and Ebneth A et al. 2010. Using electrophysiology and in silico three-dimensional modeling to reduce human Ether-a-go-go related gene K(+) channel inhibition in a histamine H3 receptor antagonist program. Assay.Drug Dev.Technol. 8: 781-789.
8. Donovan BT, Bakshi T, Galbraith SE, Nixon CJ, Payne LA, and Martens SF. 2011. Utility of frozen cell lines in medium throughput electrophysiology screening of hERG and NaV1.5 blockade. J Pharmacol Toxicol Methods 64: 269-276.
9. Dunlop J, Bowlby M, Peri R, Vasilyev D, and Arias R. 2008. High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nat.Rev.Drug Discov. 7: 358-368.
10. Farre C, Haythornthwaite A, Haarmann C, Stoelzle S, Kreir M, and George M et al. 2009. Port-a-patch and patchliner: high fidelity electrophysiology for secondary screening and safety pharmacology. Comb.Chem.High Throughput.Screen. 12: 24-37.
11. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, and Priori SG et al. 2004. Drug-induced torsades de pointes and implications for drug development. J.Cardiovasc.Electrophysiol. 15: 475- 495.
12. Finkel A, Wittel A, Yang N, Handran S, Hughes J, and Costantin J. 2006. Population patch clamp improves data consistency and success rates in the measurement of ionic currents. J Biomol.Screen. 11: 488- 496.
13. Gillie DJ, Novick SJ, Donovan BT, Payne LA, and Townsend C. 2013. Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG. J Pharmacol Toxicol Methods 67: 33-44.
14. Gintant GA, Gallacher DJ, and Pugsley MK. 2011. The 'overly-sensitive' heart: sodium channel block and QRS interval prolongation. Br.J.Pharmacol. 164: 254-259.
15. Gintant GA and Hoffman BF. 1984. Use-dependent block of cardiac sodium channels by quaternary derivatives of lidocaine. Pflugers Arch. 400: 121-129.
16. Golden AP, Li N, Chen Q, Lee T, Nevill T, and Cao X et al. 2011. IonFlux: a microfluidic patch clamp system evaluated with human Ether-à-go-go related gene channel physiology and pharmacology. Assay Drug Dev Technol 9: 608-619.
17. Guo L and Guthrie H. 2005. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. J Pharmacol Toxicol Methods 52: 123-135.
18. Hamdam J, Sethu S, Smith T, Alfirevic A, Alhaidari M, and Atkinson J et al. 2013. Safety pharmacology--current and emerging concepts. Toxicol. Appl. Pharmacol. 273: 229-241.
19. Haythornthwaite A, Stoelzle S, Hasler A, Kiss A, Mosbacher J, and George M et al. 2012. Characterizing human ion channels in induced pluripotent stem cell-derived neurons. J Biomol Screen 17: 1264- 1272.
20. Hudkins RL, Zulli AL, Dandu Rr, Tao M, Josef KA, and Aimone LD et al. 2012. 4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activity. Bioorg. Med. Chem. Lett. 22: 1504-1509.
21. Ito C. 2009. Histamine H3-receptor inverse agonists as novel antipsychotics. Cent Nerv Syst Agents Med Chem 9: 132-136.
22. Jones KA, Garbati N, Zhang H, and Large CH. 2009. Automated patch clamping using the QPatch. Methods Mol. Biol. 565: 209-223.
23. Kirsch GE, Trepakova ES, Brimecombe JC, Sidach SS, Erickson HD, and Kochan MC et al. 2004. Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods 50: 93-101.
24. Levoin N, Labeeuw O, Calmels T, Poupardin-Olivier O, Berrebi-Bertrand I, and Lecomte J et al. 2011. Novel and highly potent histamine H3 receptor ligands. Part 1: withdrawing of hERG activity. Bioorg. Med. Chem. Lett. 21: 5378-5383.
25. Milligan CJ, Li J, Sukumar P, Majeed Y, Dallas ML, and English A et al. 2009. Robotic multiwell planar patch-clamp for native and primary mammalian cells. Nat Protoc 4: 244-255.
26. Milligan CJ and Möller C. 2013. Automated planar patch-clamp. Methods Mol. Biol. 998: 171-187.
27. Moorthy NS, Ramos MJ, and Fernandes PA. 2014. Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools. J Enzyme Inhib Med Chem 29: 317-324.
28. Park S, Kim K, and Kim E. 2008. Blockade of HERG K+ channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656. J Appl Toxicol 28: 104-111.
29. Polonchuk L. 2012. Toward a New Gold Standard for Early Safety: Automated Temperature-Controlled hERG Test on the PatchLiner. Front Pharmacol 3: 3.
30. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, and Vincent GM. 1996. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 94: 1996-2012.
31. Sanguinetti MC, Jiang C, Curran ME, and Keating MT. 1995. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81: 299-307.
32. Sanguinetti MC and Tristani-Firouzi M. 2006. hERG potassium channels and cardiac arrhythmia. Nature 440: 463-469.
33. Stoelzle S, Haythornthwaite A, Kettenhofen R, Kolossov E, Bohlen H, and George M et al. 2011a. Automated patch clamp on mESC-derived cardiomyocytes for cardiotoxicity prediction. J Biomol Screen 16: 910-916.
34. Stoelzle S, Obergrussberger A, Brüggemann A, Haarmann C, George M, and Kettenhofen R et al. 2011b. State-of-the-Art Automated Patch Clamp Devices: Heat Activation, Action Potentials, and High Throughput in Ion Channel Screening. Front Pharmacol 2: 76.
35. Tye H, Mueller SG, Prestle J, Scheuerer S, Schindler M, and Nosse B et al. 2011. Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders. Bioorg.Med.Chem.Lett. 21: 34-37.
36. Wiśniowska B and Polak S. 2009. hERG in vitro interchange factors--development and verification. Toxicol. Mech. Methods 19: 278-284.
37. Zeng H, Penniman JR, Kinose F, Kim D, Trepakova ES, and Malik MG et al. 2008. Improved throughput of PatchXpress hERG assay using intracellular potassium fluoride. Assay Drug Dev Technol 6: 235-241.
38. Zhou Z, Vorperian VR, Gong Q, Zhang S, and January CT. 1999. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J. Cardiovasc. Electrophysiol. 10: 836-843